IUPAC/Chemical Name
L-Cysteinamide, N-(4-morpholinylcarbonyl)-L-phenylalanyl-N-(1-(cyclohexylmethyl)-2-hydroxy-3-(1-methylethoxy)-3-oxopropyl)-S-methyl-, (R-(R*,S*))-
SMILES Code
O=C(N)[C@H](CSC)N(C([C@H](CC1=CC=CC=C1)NC(N2CCOCC2)=O)=O)[C@@H](CC3CCCCC3)[C@@H](O)C(OC(C)C)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
Preparing Stock Solutions
The following data is based on the
product
molecular weight
620.81
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Mangiapane ML, Peters BR. Role of nitric oxide in responses to renin-angiotensin system inhibition in sodium-depleted guinea pig and rat. Clin Exp Hypertens. 1998 Feb;20(2):141-63. PubMed PMID: 9533611.
2: Allen MC, Stafford CG, Nocerini MR. Quantitation of 4-cyclohexyl-2-hydroxy-3-(3-methylsulfanyl-2- [2-[(morpholine-4-carbonyl)amino]-3-phenylpropionylamino]propi onylamino ) butyric acid isopropyl ester (CP-80,794), a renin inhibitor, and its hydrolytic cleavage metabolite 2-[(morpholine-4-carbonyl)amino]-3-phenylpropionic acid (CP-84,364) in dog and human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997 Aug 29;696(2):243-51. PubMed PMID: 9323544.
3: Shannon RP, Friedrich S, Mathier M, Knight DR. Effects of renin inhibition compared to angiotensin converting enzyme inhibition in conscious dogs with pacing-induced heart failure. Cardiovasc Res. 1997 Jun;34(3):464-72. PubMed PMID: 9231029.
4: Pitts JE, Crawford MD, Nugent PG, Wester RT, Cooper JB, Mantyla A, Fagerstrom R, Nevalainen H. The three-dimensional X-ray crystal structure of the aspartic proteinase native to Trichoderma reesei complexed with a renin inhibitor CP-80794. Adv Exp Med Biol. 1995;362:543-7. PubMed PMID: 8540369.
5: Hoover DJ, Lefker BA, Rosati RL, Wester RT, Kleinman EF, Bindra JS, Holt WF, Murphy WR, Mangiapane ML, Hockel GM, et al. Discovery of inhibitors of human renin with high oral bioavailability. Adv Exp Med Biol. 1995;362:167-80. PubMed PMID: 8540316.
6: Fossa AA, Weinberg LJ, Barber RL, Rauch AL, Nocerini MR, Murphy WR, Swindell AC. Synergistic effect on reduction in blood pressure with coadministration of the renin inhibitor, CP-80,794, and the angiotensin converting enzyme inhibitor, captopril. J Cardiovasc Pharmacol. 1992 Jul;20(1):75-82. PubMed PMID: 1383634.
